Delivery Order SPE2DB20D2002-SPE2DB25FL63P
Award Date 8/5/25
Potential Completion Date 8/6/25
Potential Value $103K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $4,212.40 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This firm fixed-price delivery order is scheduled for completion by September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's established capability to meet federal...
- The Defense Logistics Agency awarded a delivery order valued at $5,303.54 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. HEPLISAV-B is a recombinant zoster vaccine indicated for the prevention of herpes zoster in adults aged 50 years and older, representing part of the federal government's medical supply requirements for military...
- The Defense Logistics Agency awarded a $2,527.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 4, 2025, with completion scheduled for September 5, 2025. HEPLISAV-B is a recombinant zoster vaccine indicated for prevention of herpes zoster in adults 50 years of age and older. This non-set-aside award was competitively procured and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $9,743.10 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 4, 2025, with completion scheduled for September 5, 2025. This non-set-aside, firm fixed-price delivery order represents a single pharmaceutical procurement supporting federal medical supply needs. The award was made through competitive procurement processes to the prime contractor, whose corporate office is located in Conshohocken,...
- The Defense Logistics Agency awarded a $157,217.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with a completion date of July 30, 2025. HEPLISAV-B is a recombinant zoster vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 and older. This delivery order represents a non-set-aside, competitively awarded contract utilizing AmerisourceBergen's existing indefinite delivery vehicle with the DLA. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $2,106.20. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 27, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at approximately $120,283 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 micrograms per 0.5 milliliter syringes. The contract, awarded on September 4, 2025, with an ultimate completion date of September 5, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform at its corporate office...
- The Defense Logistics Agency awarded a $139,894.18 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,948.68 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a procurement of hepatitis B vaccine supplies to support federal medical requirements. The order is being fulfilled from AmerisourceBergen's place of performance in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...